Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry

被引:138
作者
Li, JN
Orlandi, R
White, CN
Rosenzweig, J
Zhao, J
Seregni, E
Morelli, D
Yu, YH
Meng, XY
Zhang, Z
Davidson, NE
Fung, ET
Chan, DW
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA
[3] Natl Canc Inst, I-20133 Milan, Italy
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Ciphergen Biosyst Inc, Fremont, CA USA
关键词
D O I
10.1373/clinchem.2005.052878
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: We previously selected a panel of 3 breast cancer biomarkers (BC1, BC2, and BC3) from serum samples collected at a single hospital based on their collective contribution. to the optimal separation of breast cancer patients and noncancer controls by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The identities and general applicability of these markers, however, were unknown. In this study, we performed protein expression profiling on samples obtained from a second hospital, included a greater number of ductal carcinoma in situ (DCIS) cases, and performed purification and identification of the 2 confirmed markers. Methods: Using a case-control study design, we performed protein expression profiling on serum samples from the National Cancer Institute (Milan, Italy). The validation sample cohort consisted of 61 women with locally invasive breast cancer, 32 with DCIS, 37 with various benign breast diseases (including 13 atypical), and 46 age-matched apparently healthy women (age range, 44-68 years). Validated biomarkers were purified and identified with serial chromatography, 1-dimensional gel electrophoresis, in-gel ASP-N digestion, peptide mass fingerprinting, and tandem mass peptide sequencing. Results: The BC3 and BC2 expression patterns in this sample set were consistent with the first study sample set. BC3 and BC2 were identified to be complement component C3a(desArg) and a C-terminal-truncated form of C3a(desArg), respectively. Conclusions: Evaluation of biomarkers in independent sample sets can help determine the broader utility of candidate markers, and protein identification permits understanding of their molecular basis. C3a(desArg) appears to lack specificity among patients with benign diseases, limiting its utility as a stand-alone tumor marker, but it may still be useful in a multimarker panel for early detection of breast cancer. (c) 2005 American Association for Clinical Chemistry
引用
收藏
页码:2229 / 2235
页数:7
相关论文
共 31 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]   Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer [J].
Adam, PJ ;
Boyd, R ;
Tyson, KL ;
Fletcher, GC ;
Stamps, A ;
Hudson, L ;
Poyser, HR ;
Redpath, N ;
Griffiths, M ;
Steers, G ;
Harris, AL ;
Patel, S ;
Berry, J ;
Loader, JA ;
Townsend, RR ;
Daviet, L ;
Legrain, P ;
Parekh, R ;
Terrett, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :6482-6489
[3]   Screening mammography under age 50 [J].
Antman, K ;
Shea, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (16) :1470-1472
[4]   Cell signals transduced by complement [J].
Bohana-Kashtan, O ;
Ziporen, L ;
Donin, N ;
Kraus, S ;
Fishelson, Z .
MOLECULAR IMMUNOLOGY, 2004, 41 (6-7) :583-597
[5]  
CARLI M, 1979, CANCER, V43, P2399, DOI 10.1002/1097-0142(197906)43:6<2399::AID-CNCR2820430634>3.0.CO
[6]  
2-T
[7]  
CHAN DW, 1999, TIETZ TXB CLIN CHEM, P390
[8]   Characterization of renal allograft rejection by urinary proteomic analysis [J].
Clarke, W ;
Silverman, BC ;
Zhang, Z ;
Chan, DW ;
Klein, AS ;
Molmenti, EP .
ANNALS OF SURGERY, 2003, 237 (05) :660-664
[9]   The human complement factor H:: functional roles, genetic variations and disease associations [J].
de Córdoba, SR ;
Esparza-Gordillo, J ;
de Jorge, EG ;
Lopez-Trascasa, M ;
Sánchez-Corral, P .
MOLECULAR IMMUNOLOGY, 2004, 41 (04) :355-367
[10]   Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems [J].
Diamandis, EP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (05) :353-356